Date	e:2022/5/7			
	r Name: Xiaoya			
Mar	nuscript Title:Express	ion and clinical signif	icance of HIF1- $lpha$, ANXA3, and CD133 in human colo	n
	cinoma	_		
Mar	nuscript number (if known):			
relat part to tr	ted to the content of your n ies whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.	
	following questions apply to nuscript only.	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>	
to th		nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.	
	em #1 below, report all sup time frame for disclosure is	•	d in this manuscript without time limit. For all other items,	
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial	al planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone		
		Time frame: pas	t 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone		
3	Royalties or licenses	XNone		

Consulting fees

X__None

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		_
	pending			
	5 5 .	V N		
9	Participation on a Data Safety Monitoring Board or	XNone		_
	Advisory Board			_
10	Leadership or fiduciary role	X None		_
10	in other board, society,			_
	committee or advocacy			_
	group, paid or unpaid			
11	Stock or stock options	X None		
	·			
12	Receipt of equipment,	XNone		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	XNone		
	financial interests			
Plea	se summarize the above co	nflict of interest in the foll	owing box:	
N	lone			

Date	e:2022/5/7		
You	r Name: Xiao V	Vu	
Man	uscript Title:Express	ion and clinical signif	icance of HIF1-α, ANXA3, and CD133 in human color
car	cinoma		
Mar	uscript number (if known):		
relat part to tr relat	ted to the content of your n ies whose interests may be ansparency and does not no tionship/activity/interest, it	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias. is preferable that you do	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third if the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so. ps/activities/interests as they relate to the current
	uscript only.	o the author's relationship	ps/activities/interests as they relate to the <u>current</u>
to the med	ne epidemiology of hyperter lication, even if that medica	nsion, you should declare tion is not mentioned in t port for the work reported	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other items,
		Name all analytes with	Constitution (Community
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		_
	pending			
	5 5 .	V N		
9	Participation on a Data Safety Monitoring Board or	XNone		_
	Advisory Board			_
10	Leadership or fiduciary role	X None		_
10	in other board, society,			_
	committee or advocacy			_
	group, paid or unpaid			
11	Stock or stock options	X None		
	·			
12	Receipt of equipment,	XNone		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	XNone		
	financial interests			
Plea	se summarize the above co	nflict of interest in the foll	owing box:	
N	lone			

Date	e:2022/5/7		
You	r Name:Jiahui	Ren	
	nuscript Title:Express cinoma	ion and clinical signif	icance of HIF1-α, ANXA3, and CD133 in human colon
Mar	nuscript number (if known):		
rela part to t	ted to the content of your n ies whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply to nuscript only.	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to t	•	nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.
	em #1 below, report all sup time frame for disclosure is	•	d in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

Consulting fees

_X__None

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		_
	pending			
	5 5 .	V N		
9	Participation on a Data Safety Monitoring Board or	XNone		_
	Advisory Board			_
10	Leadership or fiduciary role	X None		_
10	in other board, society,			_
	committee or advocacy			_
	group, paid or unpaid			
11	Stock or stock options	X None		
	·			
12	Receipt of equipment,	XNone		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	XNone		
	financial interests			
Plea	se summarize the above co	nflict of interest in the foll	owing box:	
N	lone			

Date	e:2022/5/7			
You	r Name: Kunli	Du		
Mar	nuscript Title:Express	ion and clinical signifi	icance of HIF1-α, ANXA3, and CD133 in human co	olon
	cinoma			
Mar	nuscript number (if known):			
rela part to to to rela The mar	ted to the content of your name ies whose interests may be cansparency and does not not itionship/activity/interest, it following questions apply to auscript only. author's relationships/activity ended in the pidemiology of hyperterest itication, even if that medical	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. is preferable that you do the author's relationship rities/interests should be on sion, you should declare to tion is not mentioned in the	os/activities/interests as they relate to the <u>current</u> defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive	
		None all quality and the	Considerational Community	
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as		
		needed)		
		Time frame: Since the initia	l planning of the work	
1	All support for the present	XNone		
	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article processing charges, etc.)			
	No time limit for this item.			
	No time mine for this term.			
		Time frame: past	t 36 months	
2	Grants or contracts from	X None		
	any entity (if not indicated			
	in item #1 above).			
3	Royalties or licenses	XNone		
4	Consulting fees	XNone		

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		_
	pending			
	5 5 .	V N		
9	Participation on a Data Safety Monitoring Board or	XNone		_
	Advisory Board			_
10	Leadership or fiduciary role	X None		_
10	in other board, society,			_
	committee or advocacy			_
	group, paid or unpaid			
11	Stock or stock options	X None		
	·			
12	Receipt of equipment,	XNone		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	XNone		
	financial interests			
Plea	se summarize the above co	nflict of interest in the foll	owing box:	
N	lone			

Dat	e:2022/5/7			
You	r Name:Xingy	re Wu		
Maı	nuscript Title:Express	ion and clinical signif	icance of HIF1-α, ANXA3, and CD133 in human co	olon
	cinoma			
Maı	nuscript number (if known):			
rela part to to rela The mar	ted to the content of your name ies whose interests may be ransparency and does not not interest, it following questions apply the content only. author's relationships/active epidemiology of hypertexication, even if that medical	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias. It is preferable that you do to the author's relationship vities/interests should be nsion, you should declare ation is not mentioned in the	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive	·,
		Name all entities with	Specifications/Comments	
		whom you have this relationship or indicate	(e.g., if payments were made to you or to your	
		none (add rows as	institution)	
		needed)		
		Time frame: Since the initia	al planning of the work	
1	All support for the present	X None		
	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article			
	I processing charges etc l			
	processing charges, etc.)			
	No time limit for this item.			
		Time frames nee	t 26 months	
2	No time limit for this item.	Time frame: pas	t 36 months	
2	No time limit for this item. Grants or contracts from	Time frame: pas	t 36 months	
2	No time limit for this item. Grants or contracts from any entity (if not indicated	_	t 36 months	
2	No time limit for this item. Grants or contracts from	_	t 36 months	
	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	t 36 months	

X_None

Consulting fees

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		_
	pending			
	5 5 .	V N		
9	Participation on a Data Safety Monitoring Board or	XNone		_
	Advisory Board			_
10	Leadership or fiduciary role	X None		_
10	in other board, society,			_
	committee or advocacy			_
	group, paid or unpaid			
11	Stock or stock options	X None		
	·			
12	Receipt of equipment,	XNone		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	XNone		
	financial interests			
Plea	se summarize the above co	nflict of interest in the foll	owing box:	
N	lone			

Date	e:2022/5/7		
You	r Name: Fan F	eng	
	nuscript Title:Express	ion and clinical signif	icance of HIF1-α, ANXA3, and CD133 in human colo
relar part to to to relar. The man to	ted to the content of your name ies whose interests may be cansparency and does not not ionship/activity/interest, it following questions apply to auscript only. author's relationships/activity ended in the properties of the pr	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. is preferable that you do to the author's relationship wities/interests should be go nsion, you should declare tion is not mentioned in t	os/activities/interests as they relate to the <u>current</u> defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
Â		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		_
	pending			
	5 5 .	V N		
9	Participation on a Data Safety Monitoring Board or	XNone		_
	Advisory Board			_
10	Leadership or fiduciary role	X None		_
10	in other board, society,			_
	committee or advocacy			_
	group, paid or unpaid			
11	Stock or stock options	X None		
	·			
12	Receipt of equipment,	XNone		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	XNone		
	financial interests			
Plea	se summarize the above co	nflict of interest in the foll	owing box:	
N	lone			

Date:_____2022/5/7_____

You	r Name: Jianyo	ong Zheng		
	nuscript Title:Express	ion and clinical signific	cance of HIF1-α, ANXA3, and CD133 in human	colon
	nuscript number (if known):			
rela part to tr	ted to the content of your n ies whose interests may be	nanuscript. "Related" mear affected by the content of ecessarily indicate a bias. I	elationships/activities/interests listed below that are as any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment f you are in doubt about whether to list a so.	
	following questions apply to suscript only.	o the author's relationship	s/activities/interests as they relate to the <u>current</u>	
to tł	- · · · · · · · · · · · · · · · · · · ·	nsion, you should declare a	efined broadly. For example, if your manuscript pertain II relationships with manufacturers of antihypertensive e manuscript.	
	em #1 below, report all sup time frame for disclosure is	•	in this manuscript without time limit. For all other iter	ms,
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as	,	
		needed)		
		Time frame: Since the initial	planning of the work	
1	All support for the present	XNone		
	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
2	Cuanta au cantina da fira ira	Time frame: past	36 months	
2	Grants or contracts from any entity (if not indicated	XNone		
	in item #1 above).			
3	Royalties or licenses	X None		
5	, artico or mocrisco			
4	Consulting fees	XNone		

5	Payment or honoraria for	XNone					
	lectures, presentations,						
	speakers bureaus,						
	manuscript writing or						
	educational events						
6	Payment for expert	XNone					
	testimony						
7	Support for attending meetings and/or travel	XNone					
8	Patents planned, issued or	XNone					
	pending						
	5 5 .	V N		_			
9	Participation on a Data Safety Monitoring Board or	XNone					
	Advisory Board			_			
10	Leadership or fiduciary role	X None					
10	in other board, society,						
	committee or advocacy						
	group, paid or unpaid						
11	Stock or stock options	X None					
	·						
12	Receipt of equipment,	XNone					
	materials, drugs, medical						
	writing, gifts or other						
	services						
13	Other financial or non-	XNone					
	financial interests						
Please summarize the above conflict of interest in the following box:							
N	lone						